Clinical trials · New York, NY
Ovarian cancer clinical trials in New York
We’re tracking 107 recruiting ovarian cancer studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT06203106Recruiting
NYSCF Scientific Discovery Biobank
This study collects blood, saliva, or skin samples from people with certain neurological conditions and from healthy volunteers to help researchers better understand and find treatments for these diseases.
New York, New YorkAges 4 weeks+ - NCT05349227Recruiting
After-cancer digital coaching and wearable tracking outcomes study
This study tests a digital health coaching program (using phone/tablet check-ins and wearable data) to understand health and quality-of-life outcomes after cancer treatment. It may help you learn healthy habits and track progress over time.
New York, New YorkAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
New York, New YorkAges Any age - NCT03564340RecruitingPhase 1/Phase 2
Testing ubamatamab alone or with cemiplimab for ovarian and MUC16+ cancers
This early-phase study tests ubamatamab, a cancer-targeting antibody, given by itself or with cemiplimab. It is meant to treat adults whose cancer has come back and who may not have other good standard options left.
New York, New YorkAges 18 years+ - NCT04590326RecruitingPhase 1/Phase 2
Study of REGN5668 with or without immunotherapy in ovarian cancer
This Phase 1/2 study tests how safe REGN5668 is and how well it works in adult women with advanced gynecologic cancers. It compares REGN5668 given with cemiplimab alone, or cemiplimab plus fianlimab, and looks for responses in tumors that meet specific criteria.
New York, New YorkAges 18 years+ - NCT04575935RecruitingPhase 3
Minimally invasive surgery after chemotherapy for advanced ovarian cancer
This trial studies whether doing surgery using smaller incisions after chemotherapy works as well as a more traditional approach for certain people with stage IIIC–IV ovarian, fallopian tube, or primary peritoneal cancer. It may help reduce surgical trauma while aiming for effective tumor removal.
New York, New YorkAges 18 years+ - NCT01558544Recruiting
Freezing ovarian tissue for future fertility after early menopause risk
This study looks at freezing (cryopreserving) ovarian tissue in people who are at risk of early menopause because of cancer treatment or surgery. It may help preserve natural hormone function and possible future fertility for those who cannot or do not want to freeze eggs or embryos.
New York, New YorkAges Up to 45 years - NCT06161025RecruitingPhase 2/Phase 3
Raludotatug Deruxtecan for resistant ovarian cancer
This study tests a new drug called Raludotatug Deruxtecan (R-DXd) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if R-DXd can shrink tumors or slow cancer growth.
New York, New YorkAges 18 years+ - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
New York, New YorkAges 18 years+ - NCT04751435Recruiting
Genetic testing education for cancer patients of diverse backgrounds
This study tests new educational materials about genetic testing for cancer patients. It aims to find the best ways to explain genetic testing to people from different backgrounds, especially Black, Latino, and non-Latino non-Black communities.
New York, New YorkAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
New York, New YorkAges 12 years+ - NCT06890338RecruitingPhase 2
Carboplatin and mirvetuximab for advanced ovarian cancer
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
Rego Park, New YorkAges 18 years+ - NCT05051722Recruiting
Test DNA blood and tissue markers to detect gynecologic cancers
This study looks for “methylated DNA markers” (special DNA patterns) to help detect endometrial, ovarian, and cervical cancers, and to support doctors around planned procedures. It may help find cancer earlier or better sort out who needs closer treatment.
Howard Beach, New YorkAges 18 years+ - NCT07186296Recruiting
Emerald blood test study for new cancer diagnosis
This study is testing a blood test that looks for signs of lung, breast, colorectal, pancreatic, or ovarian cancer. If you have just been told you might have one of these cancers and haven't started treatment yet, this study may be an option to help learn more about your cancer from a simple blood draw.
The Bronx, New YorkAges 45 years+ - NCT07218809RecruitingPhase 3
Comparison of AZD5335 vs standard treatments for advanced ovarian cancer
This trial tests a new drug, AZD5335, against standard treatments (mirvetuximab soravtansine or chemotherapy) for women with platinum-resistant ovarian cancer. It aims to see if AZD5335 works better based on the level of a protein called FRα on your tumor cells.
The Bronx, New YorkAges 18 years+ - NCT05799274RecruitingPhase 1
Safety study of a new PET imaging drug for cancers
This Phase 1 study tests how safe RAD301 is and how it behaves in the body when given for PET imaging in healthy volunteers and people with certain cancers. It may help doctors learn whether this imaging drug can clearly show cancer areas and be tolerated well.
The Bronx, New YorkAges 18 years+ - NCT06469281RecruitingPhase 1
A new immune cell therapy for recurring ovarian cancer
This early-phase trial tests a new immune cell therapy called 27T51, which targets a protein called MUC16 found on ovarian cancer cells. The study is for people with recurrent or treatment-resistant ovarian, primary peritoneal, or fallopian tube cancer to see if the therapy is safe and works when given alone or with other treatments.
Hackensack, New JerseyAges 18 years+ - NCT07182149RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called NRM-823 for people with several types of advanced cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
Hackensack, New JerseyAges 18 years+ - NCT06476808RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests an investigational drug (BMS-986463) in people with advanced solid tumors. It aims to find a safe dose and see if it helps shrink or control the cancer. You must be well enough to do daily activities and have a tumor that can be biopsied before treatment starts.
Hackensack, New JerseyAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Hackensack, New JerseyAges 18 years+ - NCT07444814RecruitingPhase 1
HWK-007 for advanced solid tumors
This trial tests a new drug called HWK-007, which is designed to target and attack cancer cells while sparing healthy ones. It is for people with specific advanced solid tumors (lung, endometrial, or ovarian cancer) that have not responded well to standard treatments.
Hackensack, New JerseyAges 18 years+ - NCT06774963RecruitingPhase 1
Study of LNCB74 for advanced solid tumors
This trial tests a new drug called LNCB74 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective.
Hackensack, New JerseyAges 18 years+ - NCT06756035RecruitingPhase 1
Testing CT-95 in advanced cancers with mesothelin
This trial tests a new drug (CT-95) for advanced cancers that have a marker called mesothelin. It's an early-phase study to see if the drug is safe and effective.
Hackensack, New JerseyAges 18 years+ - NCT07024784RecruitingPhase 2
Study of IMGN151 for gynecologic cancers
This study tests a new drug (IMGN151) given intravenously, alone or with other therapies, for people with certain gynecologic cancers, specifically high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and what side effects might occur.
Teaneck, New JerseyAges 18 years+
Hear when a new Ovarian cancer trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Ovarian cancer trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting ovarian cancer studies listed above.
- John Theurer Cancer Center at Hackensack University Medical Center · 6 studies
- Memorial Sloan Kettering Cancer Center · 5 studies
- Columbia University Irving Medical Center · 3 studies
- Holy Name Medical Center · 3 studies
- NYU Langone Hospital - Long Island · 3 studies
- Northwell Health Imbert Cancer Center · 2 studies
- NYU Langone Health · 2 studies
- Bronx Veterans Medical Research Foundation
What taking part in a ovarian cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting ovarian cancer studies in New York.
Common questions
- Are there ovarian cancer clinical trials near New York?
- Yes. We're currently tracking 107 recruiting ovarian cancer studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a ovarian cancer study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New ovarian cancer studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.